Skip to main content

Main menu

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Peer reviewer login
  • Journal club
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Peer reviewer login
  • Journal club
  • Alerts
  • Subscriptions

Infectious disease in respiratory medicine

Brian D. Kent
Breathe 2022 18: 220022; DOI: 10.1183/20734735.0022-2022
Brian D. Kent
1Dept of Respiratory Medicine, St James’ Hospital, Dublin, Ireland
2School of Medicine, Trinity College Dublin, Dublin, Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: briankent@physicians.ie
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

COVID-19 has brought respiratory infections into the spotlight, but other infectious diseases remain important causes of respiratory illness and death https://bit.ly/36t6Rhf

It is over a century since a respiratory disease was at the forefront of the public consciousness to the extent we see today. The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the global spread of coronavirus disease 2019 (COVID-19) have devastated lives and crippled healthcare systems around the world.

By necessity, then, the respiratory community's spotlight has been on COVID-19. But in the shadows, old foes lurk, and other respiratory infections remain important causes of morbidity and mortality.

Perhaps the oldest of these foes is Mycobacterium tuberculosis. Tuberculosis (TB) has been part of the human story since prehistory, with evidence of its baleful influence found everywhere from Egyptian mummies to Mayan temples. In the developed world, it can be easy to dismiss it as a quaint slice of Victoriana, conjuring as it may images of romantic poets wasting away elegantly, but TB remains a global menace, causing in the range of 2 million deaths every year. In this issue of Breathe, Gill et al. [1] discuss the contemporary management of TB, including the use of emerging therapies and dealing with drug-resistant strains.

The last time a respiratory pathogen caused the levels of global disease and death we have witnessed over the past 2 years was the great influenza pandemic of 1918–1919. Whilst influenza has been largely held in abeyance by the public health measures deployed to tackle COVID-19, we can be confident of its re-emergence as these measures are unwound. In parallel with this, other respiratory viruses, such as respiratory syncytial virus, are likely to make their mark. In a forthcoming article, C. Nunes-Silva and co-authors review non-COVID respiratory viral infections, including their clinical impact and treatment.

During the early stages of the COVID-19 pandemic there was widespread fear that infection with SARS-CoV-2 could be particularly problematic for people living with chronic respiratory disease. Unfortunately, this particularly proved to be the case for those with interstitial lung disease (ILD), with mortality rates approaching 50% for ILD patients hospitalised due to COVID-19 [2]. This isn't the only relationship between COVID-19 and ILD – a significant minority of patients admitted with COVID-19 pneumonia go on to develop ILD, with associated impacts on lung function and quality of life [3]. These interactions between COVID-19 and ILD are explored in detail by Myall et al. [4].

The lower airways were historically seen as a largely sterile environment, with any microbes identified within them viewed as threatening interlopers. However, as detailed in a forthcoming article by Campbell et al. [5], the lungs turn out to be home to a rich and diverse microbial flora. As they discuss, whilst the study of the respiratory microbiome is comparatively inchoate, what data we have suggests that it may play an important role in health and disease, and in determining outcomes of treatment for respiratory illness.

It is now over 2 years since the first cases of COVID-19 were reported in Europe. Inevitably, as frontline clinicians delivering care to patients with COVID-19, many colleagues working in respiratory medicine across the continent have themselves contracted the virus, with some tragically dying as a result. This issue of Breathe is dedicated to the memories of these “precious friends hid in death's dateless night”, and to other respiratory clinicians around the world who have made the ultimate sacrifice in caring for their patients.

Footnotes

  • Conflict of interest: B.D. Kent has participated in advisory boards and/or received speaker fees from AstraZeneca, Chiesi, GSK, Novartis, and Teva; has received educational travel bursaries from Boehringer Ingelheim, Chiesi, and Napp; and has received research funding from Itamar Medical.

  • Received February 18, 2022.
  • Accepted February 18, 2022.
  • Copyright ©ERS 2022
http://creativecommons.org/licenses/by-nc/4.0/

Breathe articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.

References

  1. ↵
    1. Gill CM,
    2. Dolan L,
    3. Piggott LM, et al.
    New developments in tuberculosis diagnosis and treatment. Breathe 2022; 18: 210149. doi:10.1183/20734735.0149-2021
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Drake TM,
    2. Docherty AB,
    3. Harrison EM, et al.
    Outcome of hospitalization for COVID-19 in patients with interstitial lung disease. An international multicenter study. Am J Respir Crit Care Med 2020; 202: 1656–1665. doi:10.1164/rccm.202007-2794OC
    OpenUrlPubMed
  3. ↵
    1. Myall KJ,
    2. Mukherjee B,
    3. Castanheira AM, et al.
    Persistent post-COVID-19 interstitial lung disease. An observational study of corticosteroid treatment. Ann Am Thorac Soc 2021; 18: 799–806. doi:10.1513/AnnalsATS.202008-1002OC
    OpenUrlCrossRefPubMed
  4. ↵
    1. Myall KJ,
    2. Martinovic JL,
    3. West A
    . How COVID-19 interacts with interstitial lung disease. Breathe 2022; 18: 210158. doi:10.1183/20734735.0158-2021
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Campbell CD,
    2. Barnett C,
    3. Sulaiman I
    . A clinicians' review of the respiratory microbiome. Breathe 2022; in press [https://doi.org/10.1183/20734735.0161-2022].doi:10.1183/20734735.0161-2022
PreviousNext
Back to top
Vol 18 Issue 1 Table of Contents
Breathe: 18 (1)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Infectious disease in respiratory medicine
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Infectious disease in respiratory medicine
Brian D. Kent
Breathe Mar 2022, 18 (1) 220022; DOI: 10.1183/20734735.0022-2022

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Infectious disease in respiratory medicine
Brian D. Kent
Breathe Mar 2022, 18 (1) 220022; DOI: 10.1183/20734735.0022-2022
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Footnotes
    • References
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Pulmonary vascular disease for the general respiratory clinician
  • Sleep medicine in Europe: 50 years of evolution
  • Managing respiratory disease in pregnancy
Show more Editorials

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About Breathe

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Intructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN: 1810-6838
Online ISSN: 2073-4735

Copyright © 2023 by the European Respiratory Society